Leucovorin for Cerebral Folate Deficiency
The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 75-77
DOI: 10.58347/tml.2026.1754b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.
Abstract (Originalsprache)
The FDA has approved use of oral leucovorin calcium (folinic acid) for treatment of cerebral folate transport deficiency in patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). It is the first drug to be approved for this extremely rare disorder.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Leucovorin for Cerebral Folate Deficiency. The Medical Letter on Drugs and Therapeutics, 68(1754), 75-77. https://doi.org/10.58347/tml.2026.1754b
Vancouver
Leucovorin for Cerebral Folate Deficiency. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):75-77. doi:10.58347/tml.2026.1754b
BibTeX
@article{euvimed2026,
title = {Leucovorin for Cerebral Folate Deficiency},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1754},
pages = {75--77},
doi = {10.58347/tml.2026.1754b}
}
EUVIMED